Article info
Inflammatory bowel disease
Original article
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
- Correspondence to Dr Filip Baert, Department of Gastroenterology, University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium; filip.baert{at}azdelta.be
Citation
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
Publication history
- Received June 21, 2014
- Revised March 18, 2015
- Accepted March 21, 2015
- First published April 10, 2015.
Online issue publication
June 03, 2016
Article Versions
- Previous version (10 April 2015).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/